These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25550591)

  • 1. Sunitinib-induced thyrotoxicosis - a not so rare entity.
    Jazvić M; Prpić M; Jukić T; Murgić J; Jakšić B; Kust D; Prgomet A; Bolanča A; Kusić Z
    Anticancer Res; 2015 Jan; 35(1):481-5. PubMed ID: 25550591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
    Grossmann M; Premaratne E; Desai J; Davis ID
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):669-72. PubMed ID: 18394019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
    Buda-Nowak A; Kucharz J; Dumnicka P; Kuzniewski M; Herman RM; Zygulska AL; Kusnierz-Cabala B
    Med Oncol; 2017 Apr; 34(4):68. PubMed ID: 28343336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
    Baldazzi V; Tassi R; Lapini A; Santomaggio C; Carini M; Mazzanti R
    Urol Oncol; 2012 Sep; 30(5):704-10. PubMed ID: 20884255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
    Daniels GH
    Clin Endocrinol (Oxf); 2009 Sep; 71(3):455. PubMed ID: 19138312
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
    Tassi R; Baldazzi V; Lapini A; Carini M; Mazzanti R
    Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM; Szczylik C; Rini B
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
    Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
    Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
    [No Abstract]   [Full Text] [Related]  

  • 10. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy.
    Kust D; Prpić M; Murgić J; Jazvić M; Jakšić B; Krilić D; Bolanča A; Kusić Z
    Anticancer Res; 2014 Jun; 34(6):3177-84. PubMed ID: 24922691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.
    Sato S; Muraishi K; Tani J; Sasaki Y; Tokubuchi I; Tajiri Y; Yamada K; Suekane S; Miyajima J; Matsuoka K; Hiromatsu Y
    Endocr J; 2010; 57(10):873-80. PubMed ID: 20733268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
    Sella A; Hercbergs AH; Hanovich E; Kovel S
    Chemotherapy; 2012; 58(3):200-5. PubMed ID: 22759787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
    Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.
    Del Fabbro E; Dev R; Cabanillas ME; Busaidy NL; Rodriguez EC; Bruera E
    J Chemother; 2012 Aug; 24(4):221-5. PubMed ID: 23040687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
    Nicholaou T; Wong R; Davis ID
    Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
    [No Abstract]   [Full Text] [Related]  

  • 19. Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.
    Talebi TN; Stefanovic A; Merchan J; Lian E; Silva O
    Am J Ther; 2012 Jul; 19(4):e143-5. PubMed ID: 21403468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.
    De Giorgi U; Scarpi E; Sacco C; Aieta M; Lo Re G; Sava T; Masini C; De Vincenzo F; Baldazzi V; Camerini A; Fornarini G; Burattini L; Rosti G; Ferrari V; Moscetti L; Chiuri VE; Luzi Fedeli S; Amadori D; Basso U
    Clin Genitourin Cancer; 2014 Jun; 12(3):182-9. PubMed ID: 24369790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.